

ENLITN Study

Eastern and North western Lung cancer In Never smokers


Dr Maya Bienz Clinical Oncology SpR CRUK Clinical Research Training Fellow

McCaughan Lab Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge










Study Background: LCINS

<100 cigarettes in their lifetime

- 10-25% of all lung cancer diagnoses
- LCINS 5th leading cause of cancer death for men and women worldwide (8th in UK)
- 7th most prevalent cancer in the world


Khan, S., Hatton, N., Tough, D. et al. Lung cancer in never smokers (LCINS): development of a UK national research strategy. BJC Rep 1, 21 (2023) LoPiccolo, J., Gusev, A., Christiani, D.C. et al. Lung cancer in patients who have never smoked — an emerging disease. Nat Rev Clin Oncol 21, 121–146 (2024)





Study Background: LCINS





- Majority of cases are in women (2/3)
- Present at a **younger** age
- Commonly adenocarcinomas
- Higher frequencies of driver mutations: 60-80%
- Asian ancestry
- RFs: pollution, radon, passive smoking, RT, lung disease
- Symptoms often dismissed, present late, emergency presentations
- Stigma
- The cause is poorly understood
- Little detailed information in the UK about those affected

Barlesi F, Mazieres J, Merlio JP, et al Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 2;387(10026):1415-1426.

Key Question



The majority of patients with lung cancer have a history of smoking

When someone is diagnosed with lung cancer having not smoked cigarettes a recurrent question is

"Why me?"



Aims of ENLITN



Development of a LCINS registry with paired archived tissue and blood


Comprehensive individual clinical and environmental exposure data

Germline risk and somatic mutational events related directly to environmental exposure


Is it possible to develop a risk score (based on demographics, exposure and molecular biomarkers) for future stratification of a population for screening?

Requirements of participants





Retrospective Cohort (diagnosis in past 5 years)



Prospective Cohort (recruited at diagnosis)



1. A single **blood sample** (20ml)



Consent to obtaining FFPE surgical/biopsy samples no longer needed for clinical care (no new biopsies needed)



Complete an online lifetime environmental exposure questionnaire (REDCap)

Consent for remote 5-year follow-up

A big thank you







m.bienz@nhs.net mb2702@cam.ac.uk







Dr Frank McCaughan Dr Wenrui Guo Alice Chernaik Sherine Ahmed Dr Holly Giles Leah Hurst Joanna Xie

Dr Mouhamad Ismail Michael Luo

Dr Serena Nik-Zainal Dr Helen Davies Mr Shadi Basyuni

Research teams
Patients



